• Explore /
  • Poster
  • / Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial.

Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial.

Abstract Poster

Authors

null

Pernelle Lavaud

Gustave Roussy Cancer Campus, Villejuif, France

Pernelle Lavaud , Gwenaelle Gravis , Clemence Legoupil , Florence Joly , Stephane Oudard , Franck Priou , Loic Mourey , Michel Soulie , Igor Latorzeff , Remy Delva , Ivan Krakowski , Brigitte Laguerre , Christine Theodore , Jean Marc Ferrero , Philippe Beuzeboc , Muriel Habibian , Stephanie Foulon , Jean Marie Boher , Gabrielle Tergemina-Clain , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 34, 2016 (suppl; abstr 5080)

DOI

10.1200/JCO.2016.34.15_suppl.5080

Abstract #

5080

Poster Bd #

431

Abstract Disclosures

Similar Posters

Poster

2021 Genitourinary Cancers Symposium

<em>SPOP</em> mutations in prostate cancer: Clinical and genomic features.

SPOP mutations in prostate cancer: Clinical and genomic features.

First Author: Mari Nakazawa

First Author: Lauren Christine Harshman

First Author: Miguel Angel Climent Duran

First Author: Andrew J. Armstrong